Pharma Focus Asia

Merck Invests US$27 million (€23 million) to Expand Cell Culture Media Production in USA


Merck invests US$27 million (€23 million) to expand Cell Culture Media Manufacturing facility in Kansas, USA


The facility adding 9,100 sq m2 of lab space and production capability to manufacture cell culture media, aims to enhance their capacity to produce the essential raw material used in the manufacture of life-saving therapies.

The expansion makes the largest dry powder cell culture media facility and Center of Excellence in North America.

Additionally, this investment to expand capacity with new dry powder media manufacturing lines in both Lenexa, Kansas, and Nantong, China, will not only increase local production capacity but also boost global production capacity.

This expansion demonstrates dedication to advancing biomanufacturing capabilities and ensuring a reliable supply of critical products for life-saving therapies and medical advancements.

The facility brings 60 new job opportunities.


Name           Merck
Type             New Construction
Budget          US$27 million (€23 million)


Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024